MSTN and cancer: To date, myostatin has been widely characterised as a potent negative regulator of skeletal muscle mass [7]–[9] and methods to inhibit myostatin function as a potential therapeutic treatment for increasing muscle mass in diseases such as muscular dystrophy and cancer cachexia have been explored [10], [11].